

Illicit buprenorphine use, interest in and access to buprenorphine syringe exchange participants

Journal of Substance Abuse Treatment

48, 112-116

DOI: [10.1016/j.jsat.2014.07.015](https://doi.org/10.1016/j.jsat.2014.07.015)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Harm Reduction Agencies as a Potential Site for Buprenorphine Treatment. <i>Substance Abuse</i> , 2015, 36, 155-160.	2.3	30
2	Buprenorphine infrequently found in fatal overdose in New York City. <i>Drug and Alcohol Dependence</i> , 2015, 155, 298-301.	3.2	28
3	Non-Prescribed Buprenorphine in New York City: Motivations for Use, Practices of Diversion, and Experiences of Stigma. <i>Journal of Substance Abuse Treatment</i> , 2016, 70, 81-86.	2.8	61
4	Update on Barriers to Pharmacotherapy for Opioid Use Disorders. <i>Current Psychiatry Reports</i> , 2017, 19, 35.	4.5	119
5	Buprenorphine Shared Medical Appointments for the Treatment of Opioid Dependence in a Homeless Clinic. <i>Substance Abuse</i> , 2017, 38, 26-30.	2.3	14
6	Development and evaluation of a community-based buprenorphine treatment intervention. <i>Harm Reduction Journal</i> , 2017, 14, 23.	3.2	13
7	Case 37-2017: A Man with Unintentional Opioid Overdose. <i>New England Journal of Medicine</i> , 2018, 378, 872-873.	27.0	0
8	Safe and unsafe spaces: Non-fatal overdose, arrest, and receptive syringe sharing among people who inject drugs in public and semi-public spaces in Baltimore City. <i>International Journal of Drug Policy</i> , 2018, 57, 25-31.	3.3	57
9	Buprenorphine Supply, Access, and Quality: Where We Have Come and the Path Forward. <i>Journal of Law, Medicine and Ethics</i> , 2018, 46, 272-278.	0.9	7
10	“They’re making it so hard for people to get help:” Motivations for non-prescribed buprenorphine use in a time of treatment expansion. <i>International Journal of Drug Policy</i> , 2019, 71, 118-124.	3.3	50
11	Buprenorphine in the United States: Motives for abuse, misuse, and diversion. <i>Journal of Substance Abuse Treatment</i> , 2019, 104, 148-157.	2.8	73
12	<p>Opioid Use Disorder Treatment Decision Making And Care Navigation Upon Release From Prison: A Feasibility Study</p>. <i>Substance Abuse and Rehabilitation</i> , 2019, Volume 10, 57-67.	4.8	6
13	Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107574.	3.2	33
14	Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 20.	2.6	65
15	Article Commentary: Demystifying Buprenorphine Misuse: Has Fear of Diversion Gotten in the Way of Addressing the Opioid Crisis?. <i>Substance Abuse</i> , 2019, 40, 148-153.	2.3	46
16	Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2020, 207, 107799.	3.2	7
17	Motivations for Diverted Buprenorphine Use in a Multisite Qualitative Study. <i>Journal of Drug Issues</i> , 2020, 50, 550-565.	1.2	10
18	Patterns, contexts, and motivations for polysubstance use among people who inject drugs in non-urban settings in the U.S. Northeast. <i>International Journal of Drug Policy</i> , 2020, 85, 102934.	3.3	27

#	ARTICLE	IF	CITATIONS
19	Interest in reducing methamphetamine and opioid use among syringe services program participants in Washington State. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108243.	3.2	8
20	Knowledge, preparedness, and compassion fatigue among law enforcement officers who respond to opioid overdose. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108257.	3.2	27
21	Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review. <i>Journal of General Internal Medicine</i> , 2020, 35, 954-963.	2.6	86
22	Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky. <i>International Journal of Drug Policy</i> , 2020, 85, 102701.	3.3	64
23	Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 266-272.	2.1	6
24	America's opioid crisis: the need for an integrated public health approach. <i>Translational Psychiatry</i> , 2020, 10, 167.	4.8	55
25	Principles of Integrating Opioid Use Disorder Treatment in Primary Care. , 2021, , 23-42.		0
26	Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment. <i>Journal of Addiction Medicine</i> , 2022, 16, 10-17.	2.6	6
27	Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108651.	3.2	57
28	Drug type and risk behaviors associated with non-fatal overdose among people who use drugs: a systematic review and meta-analysis. <i>Journal of Addictive Diseases</i> , 2022, 40, 114-125.	1.3	12
29	Ingenuity and resiliency of syringe service programs on the front lines of the opioid overdose and COVID-19 crises. <i>Translational Research</i> , 2021, 234, 159-173.	5.0	29
30	Strategies to improve implementation of medications for opioid use disorder reported by veterans involved in the legal system: A qualitative study. <i>Journal of Substance Abuse Treatment</i> , 2021, 129, 108353.	2.8	2
31	"It's not just writing a prescription": A qualitative study of preferences for integrated versus non-integrated treatment models among individuals with opioid use disorder. <i>Addiction Science & Clinical Practice</i> , 2021, 16, 8.	2.6	13
32	Barriers to effective care: Specialty drug treatment in Philadelphia. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108639.	2.8	2
33	Low-threshold Buprenorphine Treatment in a Syringe Services Program: Program Description and Outcomes. <i>Journal of Addiction Medicine</i> , 2022, 16, 447-453.	2.6	20
34	"Not a Good Drug Dealer": Styles of Buprenorphine Diversion in a Multisite Qualitative Study. <i>Substance Use and Misuse</i> , 2022, 57, 452-460.	1.4	1
35	Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. <i>Addiction</i> , 2022, , .	3.3	4
36	Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use. , 2022, 5, 100091.		5

#	ARTICLE	IF	CITATIONS
37	Hospital-initiated Extended-release Injectable Buprenorphine Using a Novel Reallocation Initiative From an Outpatient Addiction Medicine Clinic. <i>Journal of Addiction Medicine</i> , 2023, 17, 108-110.	2.6	1
38	“It’s the same thing as giving them CPR training”: rural first responders’ perspectives on naloxone. <i>Harm Reduction Journal</i> , 2022, 19, .	3.2	0
39	Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation. <i>Harm Reduction Journal</i> , 2022, 19, .	3.2	1
40	Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature. <i>Addiction Science & Clinical Practice</i> , 2023, 18, .	2.6	4
41	“A Lack of Empathy”: A qualitative study of Black people seeking treatment for opioid use disorder. <i>SSM Qualitative Research in Health</i> , 2023, 4, 100298.	1.5	1
42	Attitudes and beliefs about Vermont’s 2021 buprenorphine decriminalization law among residents who use illicit opioids. <i>Drug and Alcohol Dependence</i> , 2023, 250, 110879.	3.2	0
43	Beliefs and Attitudes about Vermont’s Buprenorphine Decriminalization Law among Clinicians Who Prescribe Buprenorphine. <i>Substance Use and Misuse</i> , 2024, 59, 150-153.	1.4	0
44	“I think we’re getting better but we’re still not there”: Provider-based stigma and perceived barriers to care for people who use opioids (PWUO). , 2024, 159, 209270.		1
45	Addressing buprenorphine supply barriers: A guidance commentary. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2024, 64, 377-379.	1.5	0